Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

- Investigational Study Results Published in Journal of Clinical Oncology

Pave Way for Phase II Efficacy Trial -

NUTLEY, N.J., April 18 /PRNewswire/ -- A novel biweekly dosing schedule of Xeloda(R) (capecitabine) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the April 10, 2008 issue of the Journal of Clinical Oncology. The data showed that a seven-days-on/seven-days-off (7-on/7-off) regimen, called "dose dense," was generally well-tolerated up to 2,000 mg twice daily (4,000 mg/day), providing a potential alternative to the standard Xeloda dosing of 14 days on and seven days off (14-on/7-off).

"As we predicted using the Norton-Simon mathematical model -- the basis for the dose dense approach to therapy that was pioneered at MSKCC -- these results demonstrate that a biweekly regimen of capecitabine appears to be well-tolerated, at dosing levels that are higher than previously thought possible," said Tiffany A. Traina, M.D., a medical oncologist in the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and lead author of the study. "We're currently conducting later-phase trials to determine the efficacy of this 7-on/7-off dosing schedule."

Efficacy of the 7-on/7-off schedule using Xeloda is being determined in a Phase II clinical trial program in patients with advanced breast cancer and is also being tested in combination with Avastin(R) (bevacizumab).

Breast cancer is the most common cancer among women, other than skin cancer. According to the American Cancer Society (ACS), about 182,460 women in the United States will be found to have invasive breast cancer in 2008. Breast cancer is the second leading cause of cancer death in women, after lung cancer -- about 40,930 women will die from the disease this year. Metastatic breast cancer, or cancer that has spread from the breast to othe
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
(Date:8/21/2014)... , Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and medical ... investor conferences in September: , September 4, 2014 ... , NY at 12:50 p.m. ET , September 8, ... New York , NY at 1:25 p.m. ET ...
(Date:8/21/2014)... 21, 2014  Armada Health Care (Armada), the ... is pleased to announce an agreement with Aurora ... of innovative specialty pharmacy patient program offerings. The ... management services to specialty patients via Armada,s proprietary ... Aurora will use the OTM platform as its ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3
... 23 May 2007 - The antidepressant duloxetine,hydrochloride was ... who did not respond, or responded only,partially, to ... of whether those patients were,switched from an SSRI ... presented today at the American Psychiatric,Association’s 160 th ...
... /PRNewswire/ -- With enormous,investments and the success ... need to develop effective strategies for,communicating clinical ... planning and execution will gain a significant,advantage ... and consulting firm Best Practices, LLC,successful companies ...
Cached Medicine Technology:In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
(Date:8/22/2014)... (PRWEB) August 22, 2014 ItsHot.com, a ... now offering 60-80% off on its range of beautiful ... the purchase of Gold Hearts 14K White Rose Gold ... a discount of 77%. Previously priced at $3,715.00, ... $859.00. The item code of this mesmerizing pendant embedded ...
(Date:8/22/2014)... August 22, 2014 Key West Health ... experts revealed their much anticipated study results of the ... today and released an accompanying infographic on their website. ... can have a major impact on the skin and ... and more. , When asked how they determined the ...
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” ... Luciana, is finding it challenging to stay on top of ... of hundreds of students, so the editing of the episodes ... completed, and she recently entered it into the festival circuit. ... her husband, actor/screenwriter Gregory Graham , the aging and ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Until now, those ... standard crutches or walkers to keep mobile. Thanks to an ... made much more effective. , He developed a prototype for ... an injured leg or foot but provide comfort and reduce ... to different heights, it is also convenient and easy to ...
(Date:8/22/2014)... August 22, 2014 Braverman Eye Center ... Fort Lauderdale at the most affordable fee. They are ... through their advanced Lasik treatments. LASIK is a highly ... Braverman Eye Center has been delivering successful LASIK solutions ... a glasses-free and contact lenses-free life with the help ...
Breaking Medicine News(10 mins):Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2
... Tenn., Feb. 13 Two laptop computers,are missing ... The dual-password protected laptops were used on ... Lifeblood,s blood,donors, including names, contact information, blood type, ... The organization is notifying all of the ...
... Corporation,(NYSE: SYK ) today announced that its Board ... $750 million of its common stock. Purchases may,be made ... privately negotiated,transactions or otherwise. The manner, timing and amount ... based on their evaluation of,market conditions, stock price and ...
... can lead to higher levels of severe post-natal depression (PND) and ... published in the February issue of Journal of Clinical Nursing. , ... Universite Nancy 2, France, found that just under a third of ... had PND. , Nine per cent of the women in ...
... Sun Busters(R), the swim,wear line for children that has ... protection now sports a new feature -- The Skin ... proud,to announce that they have met the high standards ... of 50+. UPF is a similar concept to SPF;,however ...
... Scientists in Switzerland are uncovering new clues about how cancer ... by studying stem cells, blank cells that have the potential ... scientists in UK have made a breakthrough in understanding the ... lymphoblastic leukaemia (ALL). The research should lead to less aggressive ...
... Procter & Gamble Company,(NYSE: PG ) today announced the following organizational ... will retire on June 1, 2008 after ... deputy general counsel, will succeed Mr. Johnson ... vice president - finance and accounting, global ...
Cached Medicine News:Health News:Two Laptop Computers Missing From Lifeblood's Main Office 2Health News:Male births are more likely to reduce quality of life and increase severe post-natal depression 2Health News:Male births are more likely to reduce quality of life and increase severe post-natal depression 3Health News:Sun Busters(R) Now Sports The Skin Cancer Foundation's Seal of Recommendation 2Health News:Sun Busters(R) Now Sports The Skin Cancer Foundation's Seal of Recommendation 3Health News:Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia 2Health News:Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia 3Health News:Procter & Gamble Announces Organizational Changes 2
Infusion Cannula, 2.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
Medicine Products: